Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Page 1
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, Samson M, Godmer P, Bonnotte B, Cottin V, Hanrotel-Saliou C, Le Gallou T, Carron PL, Desmurs-Clavel H, Direz G, Jourde-Chiche N, Lifermann F, Martin-Silva N, Pugnet G, Quéméneur T, Matignon M, Benhamou Y, Daugas E, Lazaro E, Limal N, Ducret M, Huart A, Viallard JF, Hachulla E, Perrodeau E, Puechal X, Guillevin L, Porcher R, Terrier B; French Vasculitis Study Group (FVSG). Delestre F, et al. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. Ann Rheum Dis. 2024. PMID: 37918894
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achie …
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tail …
Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: Results from the French E3N cohort.
Salliot C, Nguyen Y, Gelot A, Mariette X, Boutron-Ruault MC, Seror R. Salliot C, et al. Among authors: seror r. Joint Bone Spine. 2022 Oct;89(5):105374. doi: 10.1016/j.jbspin.2022.105374. Epub 2022 Mar 5. Joint Bone Spine. 2022. PMID: 35259476
Exposures were defined as follows: - reproductive span (in years)=duration from menarche to menopause; - total ovulatory years=reproductive span-(number of full-term pregnancies0.75+number of miscarriages0.25+total duration of breast feeding+total duration of oral contrace …
Exposures were defined as follows: - reproductive span (in years)=duration from menarche to menopause; - total ovulatory years=reproductive …
Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.
Nocturne G, Ly B, Paoletti A, Pascaud J, Seror R, Nicco C, Mackay F, Vincent FB, Lazure T, Ferlicot S, Stimmer L, Pascal Q, Roulland S, Krzysiek R, Hacein-Bey S, Batteux F, Mariette X. Nocturne G, et al. Among authors: seror r. Clin Exp Immunol. 2021 Aug;205(2):169-181. doi: 10.1111/cei.13602. Epub 2021 May 30. Clin Exp Immunol. 2021. PMID: 33864242 Free PMC article.
These data suggest a closer monitoring for lymphoma development in patients suffering from B cell-driven autoimmune disease with long-term exposure to monoclonal anti-TNF antibodies....
These data suggest a closer monitoring for lymphoma development in patients suffering from B cell-driven autoimmune disease with long-ter …
Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, Charles P, Guillevin L, Besancenot JF, Liozon E, Fauchais AL, Loffroy R, Binquet C, Audia S, Seror R, Mariette X, Bonnotte B. Samson M, et al. Among authors: seror r. Eur J Intern Med. 2018 Nov;57:96-104. doi: 10.1016/j.ejim.2018.06.008. Epub 2018 Jul 24. Eur J Intern Med. 2018. PMID: 30054122 Clinical Trial.
CONCLUSION: This study shows that an alternative strategy using a short-term treatment with TCZ can be proposed to spare GC for the treatment of GCA. ...
CONCLUSION: This study shows that an alternative strategy using a short-term treatment with TCZ can be proposed to spare GC for the t …
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group. Terrier B, et al. Ann Rheum Dis. 2018 Aug;77(8):1150-1156. doi: 10.1136/annrheumdis-2017-212768. Epub 2018 May 3. Ann Rheum Dis. 2018. PMID: 29724729 Clinical Trial.
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. ...
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutroph …
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, Belkhir R, Mariette X, Seror R; Auto-Immunity and Rituximab investigators. Henry J, et al. Among authors: seror r. Rheumatology (Oxford). 2018 Mar 1;57(3):538-547. doi: 10.1093/rheumatology/kex446. Rheumatology (Oxford). 2018. PMID: 29267905
METHODS: The Autoimmunity and Rituximab (AIR) registry is a nationwide prospective observational cohort investigating the long-term safety and efficacy of RTX in RA. The present study included patients from the AIR registry that have been re-treated with RTX after a first …
METHODS: The Autoimmunity and Rituximab (AIR) registry is a nationwide prospective observational cohort investigating the long-term s …
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.
Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit F. Strehl C, et al. Among authors: seror r. Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis-2015-208916. Epub 2016 Mar 1. Ann Rheum Dis. 2016. PMID: 26933146 Review.
As a first step to improve implementation, we aimed at defining conditions under which long-term glucocorticoid therapy may have an acceptably low level of harm. ...The group agreed that the risk of harm is low for the majority of patients at long-term dosages of 5 …
As a first step to improve implementation, we aimed at defining conditions under which long-term glucocorticoid therapy may have an a …
ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
Payet J, Belkhir R, Gottenberg JE, Bergé E, Desmoulins F, Meyer O, Mariette X, Seror R. Payet J, et al. Among authors: seror r. RMD Open. 2015 Apr 30;1(1):e000066. doi: 10.1136/rmdopen-2015-000066. eCollection 2015. RMD Open. 2015. PMID: 26509066 Free PMC article.
Elevation of acute phase reactants at inclusion was the only parameter associated with progression to erosive RA. CONCLUSIONS: Median term follow-up of ACPA-positive patients with pSS showed that almost half of them developed RA, particularly in the presence of elevation o …
Elevation of acute phase reactants at inclusion was the only parameter associated with progression to erosive RA. CONCLUSIONS: Median ter …
Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.
Zaidan M, Terrier B, Pozdzik A, Frouget T, Rioux-Leclercq N, Combe C, Lepreux S, Hummel A, Noël LH, Marie I, Legallicier B, François A, Huart A, Launay D, Kaplanski G, Bridoux F, Vanhille P, Makdassi R, Augusto JF, Rouvier P, Karras A, Jouanneau C, Verpont MC, Callard P, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Saadoun D, Ronco P, Brochériou I, Cacoub P, Plaisier E; CryoVas study group. Zaidan M, et al. J Am Soc Nephrol. 2016 Apr;27(4):1213-24. doi: 10.1681/ASN.2015020114. Epub 2015 Aug 10. J Am Soc Nephrol. 2016. PMID: 26260165 Free PMC article.
Severe infections and new-onset B-cell lymphoma occurred in 29.1% and 8.9% of cases, respectively; 24% of patients died. In conclusion, noninfectious MCGN has a poor long-term outcome with severe infections as the main cause of death....
Severe infections and new-onset B-cell lymphoma occurred in 29.1% and 8.9% of cases, respectively; 24% of patients died. In conclusion, noni …
Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X. De Vita S, et al. Among authors: seror r. Rheumatology (Oxford). 2015 Dec;54(12):2249-56. doi: 10.1093/rheumatology/kev257. Epub 2015 Aug 4. Rheumatology (Oxford). 2015. PMID: 26242856 Clinical Trial.
OBJECTIVE: To report the efficacy and safety of long-term treatment of SS with belimumab, targeting the B-cell-activating factor. ...Salivary flow, Schirmer's test and the focus score of salivary biopsy did not change. Safety of treatment was good. CONCLUSION: Long-term …
OBJECTIVE: To report the efficacy and safety of long-term treatment of SS with belimumab, targeting the B-cell-activating factor. ... …
16 results